Clinical trial
Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI
NCT00361868 · Solvay Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00361868 |
|---|---|
| Title | Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI |
| Official title | A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Rosiglitazone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dyslipidemia, Glucose Metabolism Disorder |
| Intervention type | Drug |
| Interventions | fenofibrate (F) + metformin (M) hydrochloride fixed combination, Rosiglitazone |
| Enrollment | 88 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Aug 9, 2006 |
| Last update posted | Jun 27, 2008 |
| Countries | Croatia, Finland, France, Germany, Netherlands, Poland, Romania, Ukraine |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: